Log In
Print
BCIQ
Print
Print this Print this
 

ceftobiprole medocaril (Zevtera)

Also known as: ceftobiprole (BAL5788) (formerly Zeftera)

  Manage Alerts
Collapse Summary General Information
Company Basilea Pharmaceutica AG
DescriptionProdrug of ceftobiprole, a broad-spectrum cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationPneumonia
Indication DetailsTreat community-acquired pneumonia (CAP); Treat community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Treat hospital-acquired pneumonia (HAP); Treat nosocomial pneumonia; Treat pneumonia in the hospital setting; Treat severe pneumonia in the hospital setting
Regulatory Designation

EU - Standard Review (Treat community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP));
EU - Standard Review (Treat severe pneumonia in the hospital setting);
Switzerland - Standard Review (Treat community-acquired pneumonia (CAP));
Switzerland - Standard Review (Treat hospital-acquired pneumonia (HAP))

Partner

Quintiles Transnational Holdings Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today